23 clinical trials found.
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
This study is designed to test how effective a new drug called AZD0486 (BITE for CD19) is for patients relapsed/refractory B-cell acute lymphoblastic leukemia ...
Phase
TRIAL ROLE: Principal Investigator
-
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing how effective and safe it would be to use medicine called nonconforming Idecabtagene ...
Phase N/A TRIAL ROLE: Principal Investigator
-
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing the safety and effectiveness of a medicine called nonconforming lisocabtagene maraleucel (a batch ...
Phase N/A TRIAL ROLE: Principal Investigator
-
Expanded Access Program (EAP) for Obecabtagene-Autoleucel (Obe-Cel) Out-Of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia - AUTO1-OS1
The purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured ...Phase N/A TRIAL ROLE: Principal Investigator
-
A Phase 1 Study of ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies
This is a phase 1, open-label, multicenter study with two parts that will assess the safety profile, PK profile, and preliminary efficacy of ICP-248 in ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1 First-in-human Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
This is an early-stage (Phase 1) study testing a new drug called JNJ-95804306 (an experimental cancer drug) in people with certain blood cancers, including acute ...
Phase
TRIAL ROLE: Principal Investigator
-
A Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for HOPE Patients with Hematologic Malignancies or Disorders
This in an expanded access program (EAP) to provide donor bone marrow to patients meeting eligibility criteria as well as safety in its use as ...Phase N/A TRIAL ROLE: Principal Investigator
-
EVEREST-2: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
econditioning lymphodepletion) for different cancers that express mesothelin (MSLN). First, the study team will test it on a small number of patients to see if ...
Phase
TRIAL ROLE: Sub Investigator
-
An Open-label Phase 1 Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
This study is testing a NT-112, a type of cellular therapy, in patients with advanced cancer, such as lung, pancreatic, or colorectal cancer, who have ...
Phase
TRIAL ROLE: Sub Investigator
